nifekalant Report issue

Small molecule Experimental
ChEMBL Drug Central PubChem

Active Ingredient History

NOW
  • Now
Nifekalant (INN) is a class III antiarrhythmic agent approved in Japan for the treatment of arrhythmias and ventricular tachycardia. It has the brand name Shinbit.   Wikipedia

Chemistry

  • SMILES: Cn1c(NCCN(CCO)CCCc2ccc([N+](=O)[O-])cc2)cc(=O)n(C)c1=O
  • InChIKey: OEBPANQZQGQPHF-UHFFFAOYSA-N
  • Mol. Mass: 405.46
  • ALogP: 0.33
  • ChEMBL Molecule:
    nifekalant  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

nifekalant

Organizations (4)

Research & Development (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (5)

Approved Indications (1)


 

Arrhythmias, Cardiac

Experimental Indications - Clinical Trial Phases 1-4 (5)


 

Arrhythmias, Cardiac ()

Atrial Fibrillation (Phase 4)

Heart Failure (Phase 3)

Tachycardia, Ventricular (Phase 4)

Ventricular Fibrillation (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial Organizations: 4

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue